Skip to main content
SpringerLink
Log in

Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Angiotensin II receptor blockers as a class are reported to act as insulin sensitizers. Of these, telmisartan has been shown to have additional unique peroxisome proliferator-activated receptor-gamma-mediated, insulin-sensitizing properties. In this study, investigators explored the effects of telmisartan on glycemic control and lipid metabolism in hypertensive patients with type 2 diabetes who had switched to telmisartan from another angiotensin II receptor blocker. The study subjects were 42 hypertensive outpatients with type 2 diabetes who were being treated with candesartan 8 mg/d and who agreed to switch to treatment with telmisartan 40 mg/d. Relevant laboratory variables were measured 6 mo before treatment switching, at the time of switching, and 6 mo after switching. No significant differences were noted in blood pressure, body mass index, or glycosylated hemoglobin among subjects before and after therapy was switched. No adverse reactions such as edema or hepatic toxicity were noted. No significant changes in fasting plasma glucose, fasting insulin, HOMA-R (insulin resistance as measured by the homeostasis model), preheparin lipoprotein lipase mass, high-density lipoprotein cholesterol, and free fatty acids were noted. Triglyceride levels were significantly decreased, however, and adiponectin levels were significantly increased (8.1±3.1 μg/mL at switching; 8.6±3.0 μg/mL 6 mo after switching;P<.01) after the switch to telmisartan therapy. Study results show that telmisartan did not affect glycemic control, but it improved lipid metabolism and adiponectin production in patients with type 2 diabetes, suggesting that AT1-receptor antagonism and selective peroxisome proliferator-activated receptor-gamma activation by telmisartan combine to account for observed effects on lipid metabolism and adiponectin production.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Lindholm L, Ibsen H, Bolch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.J Hypertens. 2002;20:1879–1886.

    Article  PubMed  CAS  Google Scholar 

  2. Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.Circulation. 2005;112:48–53.

    Article  PubMed  CAS  Google Scholar 

  3. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial.Lancet. 2004;63:2022–2031.

    Article  Google Scholar 

  4. Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type 1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice.Hypertension. 2004;43:1003–1010.

    Article  PubMed  CAS  Google Scholar 

  5. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems.Proc Natl Acad Sci USA. 1996;93:12490–12495.

    Article  PubMed  CAS  Google Scholar 

  6. Schling P, Loffler G. Effects of angiotensin II on adipose conversion and expression of genes of the renin-angiotensin system in human preadipocytes.Horm Metab Res. 2001;33:189–195.

    Article  PubMed  CAS  Google Scholar 

  7. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors.Diabetes. 2002;51:1699–1707.

    Article  PubMed  CAS  Google Scholar 

  8. Furuhashi M, Ura N, Takizawa H, et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity.J Hypertens. 2004;22:1977–1982.

    Article  PubMed  CAS  Google Scholar 

  9. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity.Hypertension. 2004;43:993–1002.

    Article  PubMed  CAS  Google Scholar 

  10. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activating receptor-γ activity.Circulation. 2004;109:2054–2057.

    Article  PubMed  CAS  Google Scholar 

  11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment-insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia. 1985;28:412–419.

    Article  PubMed  CAS  Google Scholar 

  12. Kobayashi J, Hashimoto H, Fukamachi I, et al. Lipoprotein lipase mass and activity in severe hypertriglyceridemia.Clin Chim Acta. 1993;216:113–123.

    Article  PubMed  CAS  Google Scholar 

  13. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan.Diabetes Care. 2004; 27:1015.

    Article  PubMed  Google Scholar 

  14. Miura Y, Yamamoto N, Tsunekawa S, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes.Diabetes Care. 2005;28:757–758.

    Article  PubMed  Google Scholar 

  15. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome.Cardiovasc Diabetol. 2005;4:6.

    Article  PubMed  Google Scholar 

  16. Okada K, Hirano T, Ran J, Adachi M. Olmesartan medoxomil, an angiotensin II receptor blocker, ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats.Hypertens Res. 2004;27:293–299.

    Article  PubMed  CAS  Google Scholar 

  17. Rangwala SM, Lazar MA. PPARγ in diabetes and metabolism.Trends Pharmacol Sci. 2004;25: 331–336.

    Article  PubMed  CAS  Google Scholar 

  18. Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors.Diabetes. 2003;52:1655–1663.

    Article  PubMed  CAS  Google Scholar 

  19. Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.Diabetes. 2001;50:2094–2099.

    Article  PubMed  CAS  Google Scholar 

  20. Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.Hypertension. 2005;46:137–143.

    Article  PubMed  CAS  Google Scholar 

  21. Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients.Diabetes Care. 1999;22:908–912.

    Article  PubMed  CAS  Google Scholar 

  22. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity.Diabetes. 2005;54:3442–3452.

    Article  PubMed  CAS  Google Scholar 

  23. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis.Hypertension. 2006;47:1–7.

    Article  Google Scholar 

  24. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice.Hypertension. 2006;48:1–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, National Hospital Organization, Utsunomiya National Hospital, 2160 Shimookamoto Kawachi-machi, Kawachi-gun, 329-1193, Tochigi, Japan

    Yutaka Mori MD & Yohta Itoh MD

  2. Department of Internal Medicine, Division of Diabetes and Endocrinology, The Jikei University School of Medicine, Tokyo, Japan

    Naoko Tajima MD

Authors
  1. Yutaka Mori MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yohta Itoh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoko Tajima MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yutaka Mori MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mori, Y., Itoh, Y. & Tajima, N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Therapy 24, 146–153 (2007). https://doi.org/10.1007/BF02850002

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850002

Keywords

Search

Navigation